Ben J.L. Van den Branden

Showing 1-8 of 8 articles

Interventions for valvular disease

Impact of mitral valve treatment choice on mortality according to aetiology

Kortlandt F, Velu J, Schurer R, Van den Branden B, Bouma B, Kelder J, Eefting F, Swaans M, Rensing B, Baan Jr J, Van der Heyden J

April 16, 2019 | 10.4244/EIJ-D-18-00874

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Teeuwen K, Van den Branden B, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

March 20, 2015 | 10.4244/EIJY14M08_07

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Van den Branden B, Teeuwen K, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

November 29, 2013 | 10.4244/EIJV9I7A138

Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II)

Teeuwen K, Van den Branden B, Rahel B, Laarman G, Thijssen J, Kelder J, Slagboom T, ten Berg J, Suttorp MJ

June 28, 2013 | 10.4244/EIJV9I2A36

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)

Van den Branden B, Rahel B, Laarman G, Slagboom T, Kelder J, ten Berg J, Suttorp MJ

February 21, 2012 | 10.4244/EIJV7I10A190

The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: comparison of mid-term efficacy and safety

Van den Branden B, Luermans J, Post M, Plokker H, ten Berg J, Suttorp MJ

September 30, 2010

Re-examining minimal luminal diameter relocation and quantitative coronary angiography - intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial

Semeraro O, Agostoni P, Verheye S, van Langenhove G, Van den Heuvel P, Convens C, Van den Branden B, Bruining N, Vermeersch P

March 20, 2009

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P

November 20, 2007

1

Latest news

A State of the Art on cardiogenic shock; a trial of balloon-based techniques for calcified lesions; a mini focus on spontaneous coronary artery dissection, and more…

August 27, 2021

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

New European insights on SCAD: are we any closer in our scientific exploration voyage?

Jacqueline Saw et al

August 27, 2021

Severely calcified coronary stenoses: a war or a battle?

Emanuele Barbato et al

September 3, 2021

ESC LATEST SCIENCE

TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type

George Dangas et al

August 26, 2021

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

Dabigatran-based dual antithrombotic therapy for patients with AF and STEMI undergoing pci

Dominick J. Angiolillo et al

August 27, 2021

Valvular disease